Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   INTERNATIONAL JOURNAL OF FERTILITY AND STERILITY   JULY-SEPTEMBER 2011 , Volume 5 , Number 2; Page(s) 90 To 95.
 
Paper: 

IS REDUCING OVARIAN VOLUME IN POLYCYSTIC OVARIAN SYNDROME PATIENTS AFTER ADMINISTRATION OF METFORMIN ASSOCIATED WITH IMPROVING CARDIOVASCULAR RISK FACTORS?

 
 
Author(s):  GHARAKHANI MOHSEN, NEGHAB NOSRAT, FARIMANI MARZIE*
 
* DEPARTMENT OF OBSTETRICS AND GYNECOLOGY, FATEMIEH HOSPITAL, HAMEDAN UNIVERSITY OF MEDICAL SCIENCES, HAMEDAN, IRAN
 
Abstract: 

Background: Women with polycystic ovary syndrome (PCOS) are at increased risk for cardiovascular (CV) and metabolic disorders. There is a close relationship between elevated androgen plasma levels and the ultrasound findings of stromal hypertrophy. In randomized trials, the administration of metformin has been shown to be followed by an improvement in insulin sensitivity and decrease in androgen levels in most women. In the present study, we investigate the association between reduced ovarian volume in PCOS patients after administration of metformin with improvement in CV risk factors.
Materials and Methods: This was a randomized clinical trial study. A total of 28 women diagnosed with PCOS who referred to the infertility clinic were selected. Anthropometric characteristics of the patients, mean ovarian volume and plasma levels of fasting blood sugar (FBS), lipid profile, luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol, testosterone, 17-
a-OH progesterone (17OHP), dehydroepiandrosterone sulfate (DHEAS), C-reactive protein (CRP) and homocysteine (Hcy) were evaluated before and after treatment with 500 mg metformin, three times daily for three months. Statistics were calculated with the aid of SPSS 16.0 with student’s paired t- and Pearson’s correlation coefficient tests. Significance was set at p<0.05.
Results: There were significant reductions in mean ovarian volume and body mass index (BMI), in addition to CRP, Hcy, testosterone, FBS, HDL and LDL levels. There was a positive correlation between mean ovarian volume and waist-to-hip ratio (WHR). After treatment, there correlation noted with reduction in mean ovarian volume and decreased BMI, in addition to reductions in CRP, LDL, Hcy and testosterone levels.
Conclusion: A positive correlation may exist between reduced mean ovarian volume and improvement in CV risk factors after administration of metformin.

 
Keyword(s): POLYCYSTIC OVARIAN SYNDROME, METFORMIN, METABOLIC SYNDROME
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
 
+ Click to Cite.
APA: Copy

GHARAKHANI, M., & NEGHAB, N., & FARIMANI, M. (2011). IS REDUCING OVARIAN VOLUME IN POLYCYSTIC OVARIAN SYNDROME PATIENTS AFTER ADMINISTRATION OF METFORMIN ASSOCIATED WITH IMPROVING CARDIOVASCULAR RISK FACTORS?. INTERNATIONAL JOURNAL OF FERTILITY AND STERILITY, 5(2), 90-95. https://www.sid.ir/en/journal/ViewPaper.aspx?id=210383



Vancouver: Copy

GHARAKHANI MOHSEN, NEGHAB NOSRAT, FARIMANI MARZIE. IS REDUCING OVARIAN VOLUME IN POLYCYSTIC OVARIAN SYNDROME PATIENTS AFTER ADMINISTRATION OF METFORMIN ASSOCIATED WITH IMPROVING CARDIOVASCULAR RISK FACTORS?. INTERNATIONAL JOURNAL OF FERTILITY AND STERILITY. 2011 [cited 2021November29];5(2):90-95. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=210383



IEEE: Copy

GHARAKHANI, M., NEGHAB, N., FARIMANI, M., 2011. IS REDUCING OVARIAN VOLUME IN POLYCYSTIC OVARIAN SYNDROME PATIENTS AFTER ADMINISTRATION OF METFORMIN ASSOCIATED WITH IMPROVING CARDIOVASCULAR RISK FACTORS?. INTERNATIONAL JOURNAL OF FERTILITY AND STERILITY, [online] 5(2), pp.90-95. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=210383.



 
  pdf-File
Yearly Visit 52
 
 
Latest on Blog
Enter SID Blog